Skip to main content

Year: 2019

Cerence to Present at Two Upcoming Investor Conferences

BURLINGTON, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that it will be participating in the following investor conferences during the month of December:2019 Raymond James Technology Investor ConferenceDate: December 10, 2019Location: New York, NYPresentation time: 9:35am ET / 12:35pm PTPresenter: Mark Gallenberger, Cerence’s Chief Financial Officer2019 Barclays Global Technology, Media and Telecommunications ConferenceDate: December 12, 2019Location: San Francisco, CAPresentation time: 7:00pm ET / 4:00pm PTPresenter: Sanjay Dhawan, Cerence’s Chief Executive OfficerA live webcast and replay of the events will be available on the Cerence Investor Relations website at https://investors.cerence.com.About Cerence Inc.Cerence (NASDAQ: CRNC) is the global industry leader...

Continue reading

Kane Biotech Announces Private Placement Offering

Not for distribution to U.S. news wire services or dissemination in the United StatesWINNIPEG, Manitoba, Dec. 04, 2019 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) today announced its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 25,000,000 units (“Units”) at a price of $0.14 per Unit for gross proceeds of up to $3,500,000. Each Unit shall be comprised of one common share and one-half of one common share purchase warrant (a “Warrant”). Each full Warrant shall entitle the holder thereof to purchase one additional common share of the Company for a period of two years, at an exercise price of $0.18 per share.The net proceeds of the Offering will be used for business development, technology and product commercialization, patent and trademark filings,...

Continue reading

iCAD’s ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging

NASHUA, N.H., Dec. 04, 2019 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Breast Health Solutions suite will be available on the Nuance® AI Marketplace. The Nuance AI Marketplace functions like an app store dedicated to radiology; it is the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform. This distribution agreement will provide iCAD consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 6,500 connected healthcare facilities.iCAD’s Breast Health Solutions suite includes ProFound AI™ for Digital...

Continue reading

BioTrackTHC and I Heart Jane to Partner for Integration

DENVER, CO, Dec. 04, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Helix TCS, Inc. (OTCQB: HLIX) subsidiary, BioTrackTHC, the leading provider of seed to sale tracking and dispensary point of sale software in the U.S., has entered into a partnership with I Heart Jane (“Jane”), the leading eCommerce software for dispensaries and brands in the U.S., to integrate the two technology platforms and offer a seamless retail experience. The integration will enable BioTrackTHC’s 2,000+ customer locations to directly integrate with Jane’s automated eCommerce platform, which provides dispensaries with turnkey content generation, delivery enablement, and powerful customer insights.The integration will bring Jane’s sleek, seamless, customer experience to the  largest customer base in the POS space. Now, Biotrack POS users can provide their...

Continue reading

Transom Capital Acquires Scantron Corporation

LOS ANGELES, Dec. 04, 2019 (GLOBE NEWSWIRE) — Transom Capital Group (“Transom”), an operations-focused middle market private equity firm, today announced it has acquired Scantron Corporation (“Scantron” or the “Company”), a global, technology and services driven company whose experts provide comprehensive assessment and technology solutions.Scantron is a widely recognized brand world-wide with a rich history in delivering quality, accuracy, reliability, and value to customers. Scantron’s Assessment Solutions division provides education assessment capabilities, licensure & certification testing solutions, and survey services to the K-12/Higher Ed, health care, financial services, and other industries globally. The company’s Technology Solutions division is a nationally-scaled provider of technology expertise which includes managed...

Continue reading

Gold Mountains (H.K.) International Mining Company Limited Completes Acquisition of Shares in the Capital of Ivanhoe Mines Ltd.

TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) — Gold Mountains (H.K.) International Mining Company Limited (“Gold Mountains”) announces the following transaction.Gold Mountains has acquired an aggregate of 35,752,011 Class A common shares of Ivanhoe Mines Ltd. (“Ivanhoe Mines”) from CITIC Metal Africa Investments Limited (“CITIC”) and an aggregate of  12,900,271 Class A common shares of Ivanhoe Mines from Mr. Robert Friedland for a price of C$3.98 per share for an aggregate subscription amount of approximately C$193,636,082 (the “Purchase”).The Purchase was effected in accordance with the terms and conditions of a share purchase agreement between Newstar Advantage Ltd., CITIC, Zijin Mining Group Co., Ltd. (“Zijin”), Gold Mountains and Mr. Robert Friedland, dated October 8, 2019.Prior to completion of the Purchase, Zijin, indirectly through...

Continue reading

Regarding the decisions adopted at the General meetings of shareholders of subsidiaries and the intention to make an official tender offer

UAB Ignitis grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.The Extraordinary General Meetings of Shareholders of Ignitis Group’s subsidiaries AB Energijos skirstymo operatorius and AB Ignitis gamyba, that were held on 4 December 2019, adopted the decision to delist all shares of AB Energijos skirstymo operatorius and AB Ignitis gamyba from trading on the Nasdaq Vilnius Stock Exchange. In accordance with the Law of the Republic of Lithuania on Securities, a formal tender offer to buy-in the issuer’s shares admitted to trading on a regulated market operating in the Republic of Lithuania must be submitted and implemented following the adoption of decision...

Continue reading

Dėl dukterinių bendrovių visuotiniuose akcininkų susirinkimuose priimtų sprendimų ir ketinimo teikti oficialų siūlymą

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.2019 m. gruodžio 4 „Ignitis grupės“ dukterinių bendrovių AB „Energijos skirstymo operatorius“ ir AB „Ignitis gamyba“ neeiliniuose visuotiniuose akcininkų susirinkimuose buvo priimtas sprendimas išbraukti visas AB „Energijos skirstymo operatorius“ ir AB „Ignitis gamyba“ akcijas iš prekybos AB Nasdaq Vilnius vertybinių popierių biržoje. Vadovaujantis Lietuvos Respublikos vertybinių popierių įstatymu, priėmus sprendimą išbraukti emitento akcijas iš prekybos Lietuvos Respublikoje veikiančioje reguliuojamoje rinkoje, privalo būti pateiktas ir įgyvendintas oficialus siūlymas supirkti...

Continue reading

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease

·        Patent extends patent coverage for eltoprazine to 2034New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that subsidiary Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s...

Continue reading

Global Restoration Holdings Completes Four Acquisitions

TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) — FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that its operating subsidiary, Global Restoration Holdings (“Global”), has recently acquired four regional restoration companies, including Perfection Property Restoration (“Perfection”), Catastrophe Cleaning & Restoration Co. (“CATCO”), ASR Property Restoration (“ASR”) and JPL Disaster Recovery (“JPL”) to join its existing brands, Interstate Restoration, FirstOnSite Restoration and Super Restoration. These acquisitions continue to build upon Global’s operational expertise and further expand its North American geographic footprint and large loss and commercial recovery & restoration service capabilities. The leaders of each of these businesses will continue to run their respective day-to-day operations....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.